Hypertension is highly prevalent in hemodialysis (HD) patients and leads to increased morbidity and mortality due to cardiovascular disease(CVD). Left ventricular hypertrophy (LVH) is both a manifestation of hypertension caused end-organ damage and an independent risk factor for CVD. Evidence shows that Beta-blockers, especially of low dialyzability decrease risk of CVD and mortality. Calcium channel blockers (CCBs) were also shown to effectively control BP in the volume expanded state and reduce cardiovascular disease risk. Asymmetric dimethyl arginine (ADMA) is a uremic toxin that decreases NO synthesis and is correlated to LVH, carotid intimal thickness (CIT), CVD, and mortality. Amlodipine is shown in one study to significantly reduce ADMA level in HD patients. The purpose of this study is to determine the effect of calcium channel blocker Amlodipine compared to Beta-blocker Bisoprolol on regression of LVH, reduction of ADMA plasma level and on BP control among hypertensive patients on HD.

Inclusion Criteria:

• On maintenance hemodialysis 3 times weekly for at least 3 months.
• Hypertensive as determined by predialytic BP > 140/ 90, post-dialytic > 130/80, home-measured BP >140/90, Office based BP >140/90 and/or on antihypertensive medication.

Exclusion Criteria:

• History of malignancy.
• History of significant valvular heart disease.
• Chronic congestive heart failure.
• History of coronary artery disease.
• Ongoing atrial fibrillation.
• Known drug abuse.
• Known contraindication to Bisoprolol or Amlodipine.
• History of MI
• History of Stroke

Data underlying results.

Starting 6 months after publication.

• Controlled access to data.
• Requests are made to the PI.
• Requests are reviewed and answered by the PI.
• Data will be provided through E-mail.